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Abstract
Familial predisposition to leukemia has been known for decades. In some 
families, this condition is also associated with thrombocytopenia and history 
of bleeding. Germline mutations in the RUNX1 gene have been proven to cause 
familial platelet disorder with predisposition to myeloid malignancies (FDPMM). 
The disease typically presents with mild-to-moderate thrombocytopenia with 
normal-size platelets, functional platelet defects leading to prolonged bleeding, 
and an increased risk to develop myelodysplastic syndrome (MDS), acute myeloid 
leukemia (AML), or T-cell acute lymphoblastic leukemia (T-ALL). In recent years, 
molecular defects in other genes, such as ANKRD26 and ETV6, have been associated 
with thrombocytopenia and susceptibility to hematological malignancy as well. In 
our chapter, we will present a review of up-to-date knowledge on this topic along 
with several case studies demonstrating the diagnostic process and management of 
the affected families.
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1. Introduction
Familial leukemia (e.g., repeated occurrence of hematologic neoplasia in families 
more often than is expected by chance alone) has been a topic of interest for decades. 
Almost a hundred years ago, connections between inherited forms of myelodysplas-
tic syndrome (MDS) and myeloid and lymphoid leukemia were established with 
several constitutional disorders in childhood, such as Fanconi anemia [1]. Since 
then, a number of additional inherited bone marrow failure syndromes and inher-
ited conditions with predisposition to leukemia were discovered. Repeated occur-
rence of similar phenotypes, high clinical penetrance for hematologic disorders, 
and often consanguineous inheritance made identification of the respective genetic 
causes easier. These conditions are caused by germline mutations (genetic changes 
which can be carried on to next generations) in genes playing an important role in 
the development and maintenance of hematopoietic system. Collective effort of 
many researchers in the past has improved the knowledge about risk for MDS/leuke-
mia, as well as the natural history and clinical outcomes of affected patients [2].
Some of these syndromes present with a distinctive hematological phenotype—
thrombocytopenia. Until the end of the last century, only a few forms of inherited 
thrombocytopenia were known, all of which were extremely rare. Since then, the 
knowledge of thrombocytopenia has improved, and we presently know at least 26 
disorders caused by mutations in 30 genes [3]. It also became quite apparent that in 
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some families, there is a connection between thrombocytopenia and additional risk 
of hematological malignancy. Thanks to availability of next-generation sequencing 
(NGS) technologies, genes associated with hereditary thrombocytopenia and risk 
of leukemic transformation were successfully identified, notably RUNX1, ETV6, 
and ANKRD26. These new hereditary syndromes were included in the 2016 revision 
of World Health Organization (WHO) classification of myeloid neoplasms and 
acute leukemia [4] (Figure 1).
2.  RUNX1 deficiency (familial platelet disorder with predisposition to 
myeloid malignancies (FPDMM))
RUNT-related transcription factor 1 (RUNX1) is a master regulator of hemato-
poiesis [5]. It is involved in the most frequent chromosome translocations in leuke-
mia (i.e., t (12;21)/RUNX1/ETV6, t(8;21)/RUNX1/RUNX1T1, and t(3;21)/RUNX1/
EVI1) [6]. Moreover, somatic RUNX1 mutations have been identified as recurrent 
abnormalities in myelodysplastic syndromes (MDS) and acute myeloid leukemia 
(AML) [7].
For the first time, germline RUNX1 mutations were described in 1999 [8]. 
Individuals carrying germline RUNX1 mutation may develop familial platelet 
disorder with predisposition to myeloid malignancies (FPDMM). Characteristic 
features include (1) thrombocytopenia, (2) functional platelet defects, and (3) an 
increased risk to develop MDS, AML, or acute T-lymphoblastic leukemia (T-ALL). 
There is a significant phenotypic heterogeneity. FPDMM (MIM601399) is inher-
ited in an autosomal-dominant mode with incomplete penetrance and variable 
 expressivity [5, 6].
Figure 1. 
Myeloid malignancies with germline predisposition. The 2016 revision to the World Health Organization 
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2.1 Diagnostic criteria to identify at-risk individuals
Diagnosis of FDPMM in patients with leukemia carries important clinical impli-
cations for the patient but also for her/his family. Recognition of clinical features 
pointing to this genetic predisposition is crucial. The most important feature is 
persistent thrombocytopenia or aspirin-like platelet disorder. Pedigree analysis can 
identify first- or second-degree relatives with higher occurrence of bleeding and 
hematological malignancies. The bleeding symptoms may be mild or not present. 
Onset of leukemia varies and spans from infant age to adulthood [9, 10]. In the case 
of family history of MDS, early-onset leukemia and/or a personal history of bleeding, 
immune deficiency, or dysmorphic features, genetic counseling is advised [11, 12].  
Comprehensive evaluation involves a thorough review of individual’s family and 
personal history, hematologic investigation, and personal risk assessment of likeli-
hood of a hereditary predisposition within his/her family, and if necessary, genetic 
testing with NGS to determine the possibility of a germline mutation should be 
offered [13]. We provide an example of a familial case of FDPMM in Figure 2 [14].
Predictive testing of healthy relatives is advised due to risk of bleeding and 
leukemia, even in infancy. In the case of individuals with leukemia, where allogenic 
stem cell transplantation from a HLA-matching sibling donor is the best possible 
treatment option, mutation screening should be a part of decision-making process, 
to prevent adverse outcomes after transplantation [15–17].
Due to the advance and widespread use of NGS technologies in diagnosis of 
myeloid neoplasia in recent years, many individuals at risk are being identified 
by screening large cohorts of patients. In particular, leukemias with homozygous 
RUNX1 mutations, biallelic RUNX1 mutations, and trisomy 21 indicate that the 
patients are likely candidates for FDPMM [18].
2.2 Platelet features
A personal or family history of thrombocytopenia and/or bleeding tendency 
may be an important pointer to diagnose FDPMM in patient with MDS, AML, 
or T-ALL. The platelet count is usually mild to moderate and, in some cases, 
low-normal and even normal. Platelet size is not affected—similar to ETV6- or 
ANKRD26-related thrombocytopenias, which are also characterized by normal-size 
platelets [19]. Thrombocytopenia is caused by abnormal megakaryocyte maturation 
and impaired proplatelet formation. Dysmegakaryopoiesis may be present in bone 
marrow smears even before leukemic transformation [20].
A functional defect of platelets is present in most, if not all, patients with 
RUNX1 germline mutations, leading to abnormal secretion and aggregation [21].
The bleeding diathesis is variable within and among families. As some carriers 
of RUNX1 have mild or none bleeding symptoms, the presence of mutation may go 
unnoticed, and genetic screening is necessary to determine mutational status.
2.3 Role of RUNX1 in hematopoiesis
The finding of platelet abnormalities in patients with FDPMM has revealed the 
essential role of RUNX1 in the megakaryocytic lineage. RUNX1 works as a transcription 
factor at different stages of megakaryocyte development by regulating the expression 
of multiple factors relevant to platelet production and function. Reduced expression of 
RUNX1 target genes, including MPL proto-oncogene, thrombopoietin receptor (MPL), 
nonmuscle myosin IIA/myosin heavy chain 9 (MYH9) and its regulatory chain MLC2, 
arachidonate 12-lipoxygenase (ALOX12), and NFE2, has been shown to cause the defect 
in platelet number and function in FDPMM [22, 23]. What is more, increased levels 
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of nonmuscle myosin IIB (MYH10), which is physiologically repressed by RUNX1, 
contribute to thrombocytopenia by blocking megakaryocyte polyploidization [24].
RUNX1 is a master regulator in hematopoietic differentiation. It plays a role 
in the first wave of hematopoiesis producing primitive erythroid cells and mega-
karyocytes. By enhanced expression of CEBPE, it negatively regulates myeloid 
progenitors and induces granulocytic differentiation. RUNX1 also regulates cell 
adhesion to the bone marrow niche [25]. After dimerizing with core-binding factor 
beta (CBFB), RUNX1 binds to promotor regions of several transcription factors like 
PU.1, regulating their expression. Binding to DNA and CBFB occurs in the highly 
conserved Runt homology domain (RHD) at the N-terminal region. Transactivation 
occurs at the C-terminal part of the molecule [26].
2.4 Phenotype/genotype correlation
Most RUNX1 mutations lie in the Runt homology domain region (RHD) [1]. 
Causative mutations are deleterious—most often frameshift, nonsense, or in/del 
mutations that result in premature protein truncation or nonsense-mediated decay 
of mRNA. Missense mutations may be present as well. In these cases, it may be 
hard to determine the pathogenicity of found variants. Here, segregation analyses 
and functional analyses are needed to confirm the effect of the variants for patho-
genesis. Loss of function mutations in RHD, located in the N-terminal part of the 
protein, impairs normal RUNX1 function by hindering dimerization and DNA 
binding. These, as well as mutations in the 5′ regulatory region cause haploinsuf-
ficiency [27]. Missense mutations in RHD and nonsense and frameshift mutations 
in the C-terminal domain may lead to dominant-negative effects [10].
What is more, there are inherited structural rearrangements involving RUNX1: 
FDPMM can also be caused by small deletions involving a few base pairs or single 
exons of the gene and large deletions leading to loss of the complete coding regions. 
Figure 2. 
Pedigree of a family with thrombocytopenia and predisposition to myeloid malignancies. We identified a 
family with platelet disorder and predisposition to myeloid malignancies. Using exome sequencing of samples 
of eight family members, we identified a pathogenic frameshift variant c.866delG (p.Gly289Aspfs*22) in 
exon 8 of RUNX1 gene, resulting in a premature stop codon. The mutation occurs within the transactivation 
domain of RUNX1. One of the affected individuals developed myelodysplastic syndrome, which progressed to 
acute myelogenous leukemia. Platelet count (PLT) reported in ×109/L, samples analyzed by exome sequencing 
marked with an asterisk (*), age of death if known [14].
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Deletions of large parts of the long arm of chromosome 21 cause a contiguous gene 
with various clinical signs, e.g., facial dysmorphism, mental retardation, thrombo-
cytopenia, and increased risk of myeloid malignancies. These large deletions can 
be reliably detected by array comparative genomic hybridization (CGH)/single-
nucleotide polymorphism (SNP) arrays [11, 12].
There seems to be a higher risk of leukemic transformation in the case of 
dominant-negative mutations of RUNx1 as compared to loss-of-function mutations. 
Both types of alterations lead to thrombocytopenia phenotype, but only dominant-
negative mutations enhance the proliferation rate and clonogenic potential [28]. 
In the case of haploinsufficiency, biallelic or second-hit mutations are needed to 
trigger the leukemic transformation.
Unfortunately, there is no clear phenotype/genotype correlation. Within one 
family, members carrying the same mutation may present with different clinical 
signs and severity of symptoms. Some carriers develop only mild thrombocytope-
nia, while others suffer from myeloid neoplasms [29].
2.5 Risk of malignancy and second-hit mutations in RUNX1 deficiency
The risk of malignant transformation into MDS or AML is estimated to be 
30–40% [16]. Patients carrying dominant-negative RUNX1 mutations have a higher 
risk of malignant transformation. The spectrum of malignancies involves AML of 
various French-American-British subtypes and MDS (refractory anemia with excess 
blasts, chronic myelomonocytic leukemia and hypoplastic MDS with myelofibrosis). 
In some cases T-cell ALL has also been described. In the case of MDS/AML, age of 
onset is at an average of 33 years with a wide age range, while in T-cell ALL, it usually 
occurs at a younger age [13, 24].
During the course of the disease, the second allele may be inactivated, as expected 
for tumor suppressor genes according to two-hit hypothesis. Nowadays, there are no 
definitive answers to what triggers the malignant transformation in RUNX1 germline 
mutation carriers. However, clonal hematopoiesis may be present even in asymptom-
atic mutation carriers, preceding overt MDS/AML or FDPMM [30].
Carriers of RUNX1 germline mutations need additional genetic events to 
develop hematological neoplasm. Often, biallelic alterations of RUNX1 are found, 
due to secondary RUNx1 mutations or acquired trisomy 21 resulting in the duplica-
tion of the mutated allele [31]. RUNx1 mutations are associated with MLL partial 
tandem duplications, FLT3-ITD, IDH1/2, RAS mutations, and ETV6 rearrange-
ments. These often occur in therapy-related AML [32]. Recently, malignant trans-
formation was reported to be mediated by recurrent somatic mutations in CD25C 
gene in up to a half of a Japanese patient cohort with RUNX1-related myeloid 
neoplasia. Next-generation sequencing allows detection of additional mutations in 
known AML drivers, such as ASXL1, TET2, IDH1, CEBPD, RB1, MLI2, FLT3-ITD, 
WT1, and SRSF2 [33, 34].
2.6 Clinical management
Treatment of RUNX1-related AML or MDS follows standard protocols. If a 
disease-causing germline mutation is known in the family, it is important to prevent 
hematopoietic stem cell transplantation from a sibling or other relative.
In families with high-penetrance mutations, regular clinical examinations 
including differential blood count are advised. In case of suspicious clinical symp-
toms or cytopenias, bone marrow aspiration or biopsy with morphological, cyto-
genetic, and molecular genetic investigations should be discussed. Using new NGS 
technologies, it is possible to follow up clonal hematopoiesis [30].
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2.7 Conclusion
RUNX1 deficiency is a myeloid malignancy predisposition syndrome with 
high clinical penetrance and variable expressivity of its phenotypic effects. An 
aspirin-like platelet and mild-to-moderate thrombocytopenia are present in most 
of the patients. The presence of possible RUNX1 germline mutations should be part 
of decision-making process in management of HSCT and donor choice in MDS/
AML. Follow-up of asymptomatic mutation carriers is necessary.
3.  ETV6-related thrombocytopenia with propensity to hematological 
malignancies
ETV6 was originally discovered in a leukemia-associated chromosomal translo-
cation [35] and has subsequently been identified as a fusion partner in more than 
30 chromosomal translocation oncogenes [36]. ETV6 is a transcriptional repressor 
that binds DNA via a C-terminal DNA-binding domain, highly conserved among 
ETS-family transcription factors [37]. The ETV6 N-terminal pointed (PNT) 
domain mediates self-association and frequently contributes to fusion proteins as 
the partner of tyrosine kinases [38]. Loss of ETV6 has firmly been implicated in the 
pathogenesis of ETV6-RUNX1(TEL-AML1)-associated childhood leukemia as there 
is invariably biallelic loss of ETV6 due to deletions of the second (nontranslocated) 
ETV6 allele [39].
More recently, genome-wide investigations have uncovered that ETV6 is subject 
to heterozygous mutations in hematologic malignancies, including myelodysplastic 
syndrome (MDS) [10, 11], acute myeloid leukemia (AML) [40], early T-cell pre-
cursor acute lymphoblastic leukemia (T-ALL) [41, 42], high-risk B-ALL [43], and 
diffuse large B-cell lymphoma (DLBCL) [44]. It remained unclear whether and how 
loss of ETV6 contributes to leukemogenesis.
Now a number of recent studies have expanded our knowledge. The initial 
report from Zhang et al. identified the link between heterozygous germline ETV6 
mutation to dominantly inherited thrombocytopenia and predisposition to hemato-
logical malignancies [45]. Subsequent studies extended these findings to additional 
families with unique ETV6 germline mutations and predisposition to malignancy 
[46, 47]. With one exception, all of the germline mutations cluster within the highly 
conserved ETS domain. The only mutation outside the ETS domain, P214L, was 
repeatedly identified in family studies.
3.1 Diagnostic criteria to identify at-risk individuals
Diagnosis of ETV6-related thrombocytopenia is paramount due to clinical impli-
cations for the patient. The most important clinical feature is thrombocytopenia 
with normal-sized platelets. Sometimes, large mean corpuscular volume (MCV) of 
red blood cells is reported. In family history, individuals with occurrence of bleed-
ing and hematological malignancies are identified. Bleeding symptoms are variable. 
No recurrent extra-hematologic abnormalities have been identified, though in some 
families, solid tumors may occur [45].
Genetic counseling, comprehensive evaluation of individual’s family and per-
sonal history, hematologic investigation, personal risk assessment of likelihood of 
a hereditary predisposition within his/her family, and, if necessary, genetic testing 
with NGS are advised. In the case of a found mutation, predictive testing of healthy 
relatives is necessary to identify at-risk individuals [13]. We provide an example 
of a familial case of ETV6 deficiency in Figure 3 [47]. In cases when allogenic 
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hematopoietic stem-cell transplantation is considered in a patient with leukemia 
and ETV6 mutation, possible sibling donors must be tested to avoid the risk of 
relapse and transplant-related morbidity and mortality.
3.2 Platelet features
All affected pedigrees with ETV6 germline mutations have a highly penetrant 
autosomal-dominant pattern of thrombocytopenia. Severity of thrombocytopenia is 
highly variable. Many patients have mild thrombocytopenia with platelet counts rang-
ing between 100 and 150 × 109/L, while others had platelet counts ˂50 × 109/L. Severe 
thrombocytopenia ˂20 × 109/L is seen rarely in the absence of myelodysplastic syn-
drome [46]. Bleeding symptoms reported are generally mild including petechiae, 
ecchymoses, epistaxis, gum bleeding, easy bruising, and menorrhagia. Platelet size is 
generally normal, though macrothrombocytopenia may be seen in a subset of patients.
Hemoglobin is normal in most patients. Erythrocyte mean corpuscular vol-
ume (MCV) is generally normal or increased. Neutrophil counts are normal. 
Examination of bone marrow reveals frequent immature hypolobulated mega-
karyocytes, mild dyserythropoiesis, and mild hypolobulation and hypogranulation 
of myeloid cells [48].
3.3 Risk of malignancy
A substantial number of patients carrying ETV6 germline mutation develop 
hematological malignancies during their lifetime. The risk of leukemic trans-
formation is estimated to be up to 25–40%; the age of onset is highly variable 
(8–82 years). The spectrum of malignancies involves acute lymphoblastic leuke-
mia (ALL) and myeloid malignancies including MDS, AML, chronic myelomono-
cytic leukemia (CMML), myeloproliferative disorders (typically polycythemia 
vera), and multiple myeloma. Special attention was brought to relationship 
between germline ETV6 mutations and childhood ALL. Targeted sequencing of 
Figure 3. 
Pedigree of a family with thrombocytopenia and occurrence of lymphoid and myeloid malignancies. We identified 
a family with autosomal dominant thrombocytopenia, high erythrocyte mean corpuscular volume (MCV), 
occurrence of B cell-precursor acute lymphoblastic leukemia (ALL) and myeloproliferative neoplasm (MPN). 
Whole-exome sequencing identified a heterozygous single-nucleotide change in ETV6 (ETS variant 6), c.1138T>A, 
encoding a p.Trp380Arg substitution in the C-terminal DNA-binding domain, segregating with thrombocytopenia 
and elevated MCV. The role of Trp380 is structural, being surrounded by hydrophobic residues in the domain 
hydrophobic core. Its substitution by an arginine will therefore severely destabilize the domain structure. Platelet 
count (PLT) reported in ×109/L, samples analyzed by exome sequencing marked with an asterisk [47].
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a large cohort of childhood ALL patients revealed 31 leukemia-associated ETV6 
exonic variants [49]. All variants in this study were absent in control population. 
About 48% of found variants were found in the ETS DNA-binding domain and 
were predicted to be deleterious. Children with ETV6 variants were older at diag-
nosis (median 10.2 years) than those without ETV6 variants (4.7 years). There 
was no association between ETV6 mutation status and early treatment response 
or risk of relapse.
In some families, a few sold tumors have been reported: colorectal carcinoma, 
breast cancer, renal cell carcinoma, and tumor of the central nervous system. Further 
investigation is needed to understand the role of ETV6 in solid tumors [45, 49, 50].
3.4 Mutation spectrum
The mutation types in ETV6-related thrombocytopenia with predisposition to 
malignancies include nonsense, missense, splice site, and frameshift variants. The 
majority of mutations cluster within the ETS DNA-binding domain and are pre-
dicted to be deleterious. The p214L mutation, which resides in the linker region, has 
been recurrently identified in different families [45, 49].
3.5 Second-hit mutations in ETV6 deficiency
The development of leukemia with variable latency and incomplete penetrance 
suggests a need for further somatic mutations. Studies did not reveal mutations in 
the remaining wild-type ETV6 allele in most cases. Such examples are more of an 
exception. Acquisition of somatic defects in other genes, such as RUNX1, BCOR, 
and KRAS, is more prominent. The role of additional mutations in malignant 
transformation remains to be determined [45].
3.6 Molecular structure and role of ETV6
ETV6 is a part of a 26-member family of transcriptional regulators, defined 
by a highly conserved 85-amino-acid residue that mediates binding of target 
DNA. Different ETS factors can replace each other in the context of  
overexpression in vitro but exhibit functional diversity and individual  
specificity in DNA binding beyond the core motif. ETV6 has the capacity to form 
polymers with head-to-tail binding of two different protein surfaces within its PNT 
domain [51].
The primary function of ETV6 is a transcriptional repressor. The PNT domain-
mediated multimerization is required for high affinity DNA binding. Truncated 
ETV6 proteins resulting from frameshift mutations retaining either the PNT 
domain or the ETS domain were shown to exhibit a dominant-negative activity. This 
was also demonstrated for the familial germline mutations. This may suggest that 
the pathogenic activity of ETV6 mutations not only includes loss of function but 
also interferes with the wild-type allele [40, 52, 53].
ETV6 also plays an important role in embryonic development.  
Homozygous ETV6 germline disruption results in embryonic lethality in mice 
studies [54]. ETV6 is required for survival of hematopoietic stem cells in the 
bone marrow. It also promotes the late phases of megakaryopoiesis. Heterozygous 
disruption of ETV6 in mice is not associated with obvious phenotypes, implying 
the dominant-negative effect of germline mutations found in affected families: 
complete loss of ETV6 is lethal, but development of abnormalities requires more 
than heterozygous loss [55, 56].
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3.7 Clinical management
Treatment of ETV6-related leukemia does not differ from standard protocols. 
As in FDP-MM, if a disease-causing germline mutation is known in the family, it 
is necessary to test siblings, as HSCT from a sibling carrier of ETV6 pathogenic 
variant should be avoided. Family members should be tested, and regular follow-up 
of mutation carriers including differential blood count is advised. Bone marrow 
aspiration and/or biopsy with thorough cytogenetic/molecular genetic investiga-
tion may be necessary in case of additional cytopenias or other suspicious clinical 
symptoms [13].
3.8 Conclusion
Discovery of familial ETV6 germline mutations has established its clinical signifi-
cance as a cause of thrombocytopenia, as well as a major cancer predisposition gene, 
associated with a substantial number of childhood B-ALL cases as well as myeloid 
malignancies. However, our understanding of the clinical impact of ETV6 mutations 
and physiological role of ETV6 remains incomplete. More work is needed to understand 
the molecular pathology of the mutations and stratify the risk of affected individuals.
4. ANKRD26-related thrombocytopenia
Thrombocytopenia 2 (THC2 MIM 188000) is one of the rarest forms of auto-
somal-dominant thrombocytopenia. It has so far been reported only in 21 families 
across the world [57]. The THC2 locus was mapped to chromosome 10p11.1-p12 
through linkage analysis in two independent studies [58, 59]. In the original studies, 
two missense changes in different linked genes were found to be causative of the 
disease: c.501G > C (p.Glu167Asp) and c.22 C > T (p.his8Tyr). Another study identi-
fied pedigrees with six additional ANKRD26 mutations, segregating with throm-
bocytopenia. All of them were located in a stretch of 19 nucleotides of the 5′ UTR 
that is highly conserved in evolution. These findings associate ANKRD26 5 ′ UTR 
mutations with thrombocytopenia [60]. Further reports extended the number of 
known families to 21 [61]. The abovementioned studies also found that the number 
of hematologic malignancies was higher than expected.
4.1 Diagnostic criteria, platelet features
THC2-affected individuals have a degree of thrombocytopenia ranging from 
mild to severe and suffer from a mild bleeding diathesis. Major bleeding events 
are rare. Platelets are normal-sized and morphology does not reveal any defects. 
Examination of bone marrow shows dysmegakaryocytopoietic phenomena. No 
other changes in blood count, e.g., anemia and neutropenia, were reported [60].
4.2 Risk of malignancy
A comprehensive study of 118 subjects affected with THC2 identified 10 patients 
who developed myeloid malignancies: four acute myeloid leukemias (AML), 
four myelodysplastic syndromes, and two chronic myeloid leukemias (CML). 
Cumulative incidence of hematological malignancies in this subset of patients is 
8.47%. The incidence of lymphoproliferative disorders and nonhematologic cancers 
was not higher than expected. Available data are compatible with the hypothesis 
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that ANKRD26-related thrombocytopenia predisposes to myeloid malignancy. 
However, penetrance for neoplasia is incomplete, and other genetic or environmen-
tal factors must contribute to development of these disorders [57].
4.3 Molecular genetics
ANKRD26 is the ancestor of a family of primate-specific genes termed POTE 
(prostate-ovary-testes- and placenta-expressed genes) whose expression is 
restricted to several normal to a few normal tissues and a larger number of malig-
nancies, such as breast cancer. ANKRD26 is expressed also in megakaryocytes and 
to lesser extent erythroid cells [62, 63].
The functional role of ANKRD26 is unknown. Deleterious mutations of 
aNKRD26 in animal studies do not cause thrombocytopenia. This evidence sug-
gests that THC2 is more likely to be caused by gain-of-function mutations rather 
than haploinsufficiency. It is suspected that mutations in the 5′ UTR interfere with 
mechanisms controlling the expression of ANKRD26 and affect megakaryopoiesis 
and platelet production, possibly by induction of apoptosis [60, 64].
4.4 Clinical management
As in the abovementioned entities, screening for ANKRD26 mutations must be 
a part of diagnostic process in hereditary thrombocytopenia and familial myeloid 
leukemia. Follow-up of asymptomatic mutation carriers in regular intervals includ-
ing peripheral blood count and smear is necessary. The presence of ANKRD26 
germline mutations in acute leukemia may also play a part in HSCT-related 
questions.
4.5 Conclusions
ANKRD26 is a rare form of inherited thrombocytopenia with low risk of 
bleeding and predisposition to myeloid malignancies. Recognition of this disorder 
is important in differential diagnosis of hereditary thrombocytopenia and proper 
management of affected subjects.
5. Further candidate genes
There are several genes associated with inherited bone marrow failure syn-
dromes (IBMFS) and thrombocytopenia, notably MPL, THPO, HOXA11, MECOM, 
and RBM8A, as well as mutations in genes for X-linked thrombocytopenia and 
immune deficiency (GATA1, WAS) [65]. These clinical entities present with throm-
bopenia or pancytopenia and, in some cases, dysmorphic features. The IBMFS are 
complex disorders unified by development of bone marrow failure and increased 
risk of leukemic transformation. In some IBMFS, the steps toward leukemic 
transformation are better understood. In others, there is still much to learn. The 
estimated risk of malignancy in the abovementioned entities requires additional 
research.
MYH9 mutations result in congenital macrothrombocytopenia and predispose 
to kidney failure, hearing loss, and cataracts. There are a few published cases of 
germline mutations of MYH9 with myeloid malignancy [66]. Somatic expression 
of MYH9 has impact on overall survival in patients with AML [67]. However, 
additional studies on larger patient populations are needed to confirm this 
suspicion.
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6. Conclusion
In this chapter, we have summarized current knowledge of familial syndromes 
with thrombocytopenia and predisposition to hematologic malignancies. These 
rare disorders must be a part of differential diagnosis of (1) unexplained or familial 
thrombocytopenia, (2) myeloid malignancies with familial occurrence, and (3) 
bone marrow failure syndromes. Only a correct diagnosis with up-to-date hemato-
logical and molecular diagnostics can lead to proper follow-up of affected individu-
als and families. Personalized risk assessment must be made; and in the case of a 
familial germline mutation, genetic reproductive consultation should be offered.
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